Pharmaceutics · 8 authors, 2 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This preclinical study used a mouse model of retinal ischemia-reperfusion to test the neuroprotective effects of topical fluoxetine. The central result was that fluoxetine treatment preserved retinal function and reduced inflammatory markers and glial activation after ischemic injury.
The study investigated the neuroprotective potential of fluoxetine in a mouse model of retinal ischemia-reperfusion injury, which mimics aspects of glaucoma. The discussion positions these findings within the context of neuroinflammation as a key factor in retinal diseases like glaucoma. The implications suggest fluoxetine could be a candidate for further clinical evaluation for glaucoma, though this remains preclinical evidence.
